FinTrust Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

FinTrust Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.69K	Hold	15	–	–	﹤0.01%	1230
2024 Q2	$2.02K	Hold	15	–	–	﹤0.01%	1193
2024 Q1	$2.02K	Hold	15	–	–	﹤0.01%	1101
2023 Q4	$1.93K	Sell	15 -2,000	-99%	-$230K	﹤0.01%	1081
2023 Q3	$227K	Buy	2,015 +515	+34%	+$54.2K	0.05%	244
2023 Q2	$141K	Sell	1,500 -1,000	-40%	-$97.7K	0.03%	304
2023 Q1	$253K	Hold	2,500	–	–	0.06%	227
2022 Q4	$299K	Buy	+2,500	New	+$293K	0.07%	209
2021 Q3	–	Sell	-118	Closed	-$11K	–	1191
2021 Q2	$11K	Hold	118	–	–	﹤0.01%	918
2021 Q1	$11K	Sell	118 -35	-23%	-$3.67K	﹤0.01%	875
2020 Q4	$15K	Sell	153 -41	-21%	-$3.96K	﹤0.01%	740
2020 Q3	$19	Sell	194 -239	-55%	-$27.6K	﹤0.01%	662
2020 Q2	$53K	Buy	+433	New	+$47.9K	0.02%	474
2019 Q2	–	Sell	-2	Closed	–	–	1179
2019 Q1	$0	Hold	2	–	–	﹤0.01%	1311
2018 Q4	$0	Buy	+2	New	+$192	﹤0.01%	1295

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FinTrust Capital Advisors's NBIX Position: Q3 2024 in Review

FinTrust Capital Advisors held its Neurocrine Biosciences (NBIX) position steady in Q3 2024 at 15 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1230.

FinTrust Capital Advisors first reported a position in NBIX in Q4 2018 and has held it in 15 quarters since. The position peaked at $299K in Q4 2022. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

FinTrust Capital Advisors held 15 shares of Neurocrine Biosciences worth $1.69K as of Q3 2024.
FinTrust Capital Advisors left its Neurocrine Biosciences share count unchanged in Q3 2024.
Neurocrine Biosciences made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1230 holding.
FinTrust Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 15 quarters since.
FinTrust Capital Advisors's Neurocrine Biosciences position peaked at $299K in Q4 2022.
574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.